Back to Journals » Therapeutics and Clinical Risk Management » Volume 16

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema

Authors Giarmoukakis AK, Blazaki SV, Bontzos GC, Plaka AD, Seliniotakis KN, Ioannidi LD, Tsilimbaris MK

Received 10 July 2020

Accepted for publication 12 September 2020

Published 6 November 2020 Volume 2020:16 Pages 1067—1074

DOI https://doi.org/10.2147/TCRM.S271184

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Athanassios K Giarmoukakis,* Styliani V Blazaki,* Georgios C Bontzos, Argyro D Plaka, Konstantinos N Seliniotakis, Larissa D Ioannidi, Miltiadis K Tsilimbaris

Department of Ophthalmology, University Hospital of Heraklion, Heraklion, Greece

*These authors contributed equally to this work

Correspondence: Miltiadis K Tsilimbaris
University Hospital of Heraklion, Heraklion 71003, Crete, Greece
Tel +302810392351
Fax +302810392730
Email tsilimb@med.uoc.gr

Purpose: To assess the effect of twice-daily nepafenac ophthalmic suspension 0.3% on postoperative cystoid-macular-edema (CME).
Patients and Methods: In this prospective, clinic-based, non-randomized case-series, 21 patients (21 eyes) were enrolled with either acute or chronic postoperative CME after cataract extraction. Patients were treated with twice-daily nepafenac 0.3% drops, and followed for at least a 4-month period. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT)-derived central retinal thickness (CRT) were measured.
Results: From 21 patients, eight presented with acute postoperative CME and 13 with chronic CME. Mean follow-up was 4.82± 1.24 months. No adverse events were reported during the study. Baseline BCVA was 0.49± 0.36 logMAR and improved to 0.36± 0.42 logMAR at the last follow-up visit (P< 0.005). CRT decreased from 450.40± 90.74 μm at baseline to 354.60± 81.49 μm (P< 0.05), following treatment.
Conclusion: Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.

Keywords: nepafenac, postoperative macular edema, cataract operation, topical use, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]